NazlinR - Transnasal Systemic Delivery of Insulin
I recently had a discussion with a scientist from a major “Eastern Establishment” pharmaceutical company in the U.S. The topic of our discussion was the success of this young upstart biotechnology industry. Although we were in agreement that biotechnology allows for a more rational approach to design of therapeutic agents, he argued that, “you cannot make it in the pharmaceutical industry simply on injectable hormones”. Whether or not the economic argument is valid, it is clear that widespread, patient-controlled use of therapeutic proteins and peptides demands an alternative to parenteral administration. The most likely route of administration for this relatively new and rapidly expanding class of therapeutic agents is via the nasal cavity. The highly vascularized mucosal surfaces of the nasal passages, the ease of administration, potential advantages of no first pass metabolism and the rapid kinetics of absorption make the nasal route an ideal alternative to parenteral administration. Transnasal systemic drug delivery has become a popular topic (Parr, 1983; Su, 1986) and was the subject of a recently published Symposium held at Rutgers University in New Jersey (Chien, 1985). The message from this meeting was that nasal drug delivery is indeed a viable alternative with significant therapeutic and kinetic advantages, especially for hormones. However, problems of bioavailability, reproducibility of plasma levels and effect on nasal pathology, i.e., local toxicity, remain to be solved.
KeywordsBile Salt Insulin Dose Cholic Acid Therapeutic Protein Critical Micellar Concentration
Unable to display preview. Download preview PDF.
- Carey, M.C. and Small, D.M.; 1973 Solution properties of taurine and glycine conjugates of fusidic acid and its derivatives, Biochim et Biophys. Acta 305:51.Google Scholar
- Chien, Y.W., 1985 “Transnasal Systemic Medications: Fundamentals, Developmental Concepts and Biomedical Assessments” Elsevier-Amsterdam.Google Scholar
- Collens, W.S. and Goldzieher, 1932, Absorption of insulin by nasal mucous membrane, Proc. Soc. Exp. Bio. Med., 29: 756.Google Scholar
- Galloway, J.A.; Spradlin, C.T.; Nelson, R.L.; Wentworth, S.M.; Davidson, J.A. and Swarner, J.L. 1981, Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care, 3: 366.CrossRefGoogle Scholar
- Jeffery, P.D., Milthorpe, B.K. and Nichol, L.W., 1976, Polymerization pattern of insulin at ph 7.0, Biochemistry, 15: 4460.Google Scholar
- Parr, G.D., 1983, Nasal delivery of drugs, Pharm. Int. Aug:202.Google Scholar
- Salzman, R.; Manson, J.E., Griffing, G.T.; Kimmerle, R.; Ruderman, N.; McCall, A.; Stoltz, E.I.; Mullin, C.; Small D.; Armstrong, J. and Melby, J.C., 1985, Intranasal aerosolized insulin: mixed meal studies and long-term use in type I diabetes N. Engl. J. Med., 312: 1078.PubMedCrossRefGoogle Scholar
- Scholmerich, J.; Becher, M.S.; Schmidt, K.; Schubert, R.; Kremer, B.; Feldhaus, S. and Gerok, W., 1984, Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties — studies on isolated hepatoyates and lipid membrane vesicles, Hepatology, 4: 661.PubMedCrossRefGoogle Scholar
- Su, K.S.E.; 1986, Intranasal delivery of peptides and proteins, Pharm. Int., 7: 8.Google Scholar
- Woodyatt, R.T., 1922, The clinical use of insulin, J. Metab. Res., 2: 793.Google Scholar